Name: 글로벌 시장 동향
SKU: PH7892
Availability: InStock

보고서 요약(국문)

개요
전 세계 난치성 간질 지속상태 치료제 시장은 2022년 XX억 달러에 달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 보이며 2030년에는 XX억 달러에 이를 것으로 예상됩니다.
난치성 간질 지속상태는 두 가지 정맥 투여 약물(그중 하나는 벤조디아제핀)에도 반응하지 않는 지속적인 발작을 말합니다. 간질 지속상태 환자의 최대 40%에서 나타나며, 급성 증상성 발작이 가장 흔한 원인입니다.
난치성 간질 지속상태 치료에 사용되는 약물로는 로라제팜과 디아제팜을 포함한 벤조디아제핀이 있습니다. 또한, 페니토인, 포스페니토인, 발프로산과 같은 항간질제와 미다졸람, 프로포폴과 같은 마취제도 사용됩니다. 마지막으로, 펜토바르비탈과 티오펜탈과 같은 바르비투르산염 계열 약물은 난치성 간질지속상태 치료에 사용되는 시판 치료제 중 일부입니다.
미국 국립 의학 도서관(NLM)에 따르면, 난치성 간질지속상태 치료에 사용되는 다른 새로운 약물 및 치료법으로는 저체온 요법, 스테로이드, 면역억제제, 전기 및 자기 자극 요법, 응급 간질 수술, 케토제닉 식이요법, 피리독신 주입, 뇌척수액 배액, 마그네슘 주입 등이 있습니다.
시장 동향
간질지속상태 치료를 위한 기업들의 새로운 치료법 발표 증가
간질지속상태 치료를 위한 기업들의 새로운 치료법 발표 증가는 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2023년 6월 21일, 마리누스 제약(Marinus Pharmaceuticals)은 간질지속상태 치료를 위한 정맥주사 가낙솔론(IV Ganaxolone)의 새로운 사용 방법에 대한 특허를 미국 특허청(USPTO)으로부터 획득했다고 발표했습니다. FDA의 소프트웨어 승인 증가 및 메디케어·메디케이드 서비스 센터(CMS)의 신기술 추가 지불(NTAP) 적용 확대
CMS의 NTAP 적용 확대에 따라 기업 소프트웨어에 대한 FDA 승인이 증가하면서 전 세계 난치성 간질 지속상태 치료제 시장의 성장이 촉진될 것으로 예상됩니다.
예를 들어, 2023년 8월 FDA는 18세 이상 성인의 뇌파상 간질 지속상태(ESE) 진단을 위한 세리벨(Ceribell)의 새로운 소프트웨어인 클래리티프로(ClarityPro)에 510(k) 승인을 부여했으며, 이는 해당 분야에서 시장 최초로 사용 가능한 도구가 되었습니다. 또한 CMS는 클래리티프로에 대해 적격 메디케어 환자 사례당 최대 913.90달러의 신기술 추가 지불(NTAP)을 제공했습니다. 따라서 이러한 요인들로 인해 향후 시장 성장이 촉진될 것으로 전망됩니다.

엄격한 규제 요건
제약 부문은 특히 난치성 간질 지속상태와 같은 중증 질환 치료제 개발과 관련하여 여러 법률 및 규정의 적용을 받습니다. 유럽의약품청(EMA) 및 미국 식품의약국(FDA)과 같은 기관의 규제 승인을 받는 것은 어렵고 시간이 오래 걸릴 수 있습니다. 이러한 요건을 충족하는 데 시간이 소요되어 새로운 난치성 간질 지속상태 치료제의 시장 출시가 지연될 수 있으며, 결과적으로 환자의 치료 선택권이 줄어들 수 있습니다.
세분화 분석
전 세계 난치성 간질 지속상태 치료제 시장은 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
약물 유형 중 벤조디아제핀이 예측 기간 동안 시장을 주도할 것으로 예상됩니다.
약물 유형 중 벤조디아제핀은 34.5%의 시장 점유율로 난치성 간질 지속상태 치료제 시장을 주도할 것으로 예상됩니다. 예를 들어, 2022년 6월, 벤조디아제핀 계열의 항경련제 치료는 소아에서 발생하는 간질 지속상태의 약 62%를 성공적으로 억제했습니다. 1차 치료에는 일반적으로 발작을 유발하는 과도한 신경 세포 활동을 억제하는 벤조디아제핀이 포함됩니다.
지역별 시장 점유율
북미, 전 세계 난치성 간질 지속상태 치료제 시장에서 최대 시장 점유율 차지
북미는 2022년 기준 전 세계 난치성 간질 지속상태 치료제 시장에서 약 41.3%의 시장 점유율을 차지하며 시장을 주도하고 있습니다. 또한, 2022년 3월 미국 식품의약국(FDA)은 2세 이상 환자의 CDKL5(cyclin-dependent kinase-like 5) 결핍 장애(CDD) 관련 발작 치료제인 즈탈미(Ztalmy, 가낙솔론)를 승인했습니다. CDD는 CDKL5 유전자 변이로 인해 발생하는 희귀 발달성 간질성 뇌병증(뇌 기능 장애)입니다. 따라서 위와 같은 요인들로 인해 북미는 예측 기간 동안 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다.
경쟁 환경
시장의 주요 글로벌 기업으로는 Pfizer, Almatica Pharma LLC., Teva Pharmaceuticals USA, Inc., Genentech, Inc., Viatris Inc., NAYZILAM, SiNi Pharma Pvt Ltd, H. Lundbeck A/S, Wellona Pharma 및 Bausch Health Companies Inc 등이 있습니다.

시장 세분화
약물 유형별
• 벤조디아제핀계
o 로라제팜
o 디아제팜
• 항간질제
o 페니토인
o 포스페니토인
o 발프로산
o 기타
• 마취제
o 미다졸람
o 프로포폴
• 바르비투레이트계
o 펜토바르비탈
o 티오펜탈
o 기타
투여 경로별
• 경구
• 정맥 주사(IV)
• 근육 주사(IM)
• 설하 또는 협측 투여
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
• 아시아 태평양 지역 (기타)
• 중동 및 아프리카
주요 동향
• 2021년 2월, 마리누스 파마슈티컬스(Marinus Pharmaceuticals)는 정맥주사(IV) 가낙솔론(ganaxolone)의 3상 RAISE 임상시험에 첫 환자를 등록했다고 발표했습니다.
보고서 구매 이유

• 약물 유형, 투여 경로, 유통 채널 및 지역별 전 세계 난치성 간질 지속상태 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.

• 모든 세그먼트를 포함한 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트가 제공됩니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서입니다.

• 주요 기업의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일이 제공됩니다.

전 세계 난치성 간질 지속상태 치료제 시장 보고서는 약 61개의 표, 61개의 그림, 227페이지로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Refractory Status Epileptics Drugs Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
Refractory status epilepticus are referred to as persistent seizures that are resistant to two intravenous drugs, one of which is a benzodiazepine. Up to 40% of status epilepticus instances exhibit it, with acute symptomatic etiology being the most likely reason.
Drugs used for the the treatment of refractory status epileptics are benzodiazepines which include lorazepam and diazepam. Moreover, antiepileptic drugs include phenytoin, fosphenytoin, and valproic acid. Furthermore, anaesthetic agents such as midazolam and propofol. Lastly, barbiturates such as pentobarbital and thiopental are some of the treatments available in the market used for the treatment of refractory status epileptics.
Some of the other emerging drugs and methods used for the treatment of refractory status epileptics according to the National Library of Medicines(NLM), include hypothermia, steroids, immunosuppressive agents, electrical and magnetic stimulation therapies, emergent respective epilepsy surgery, ketogenic diet, pyridoxine infusion, cerebrospinal fluid drainage, and magnesium infusion.
Dynamics
Increase in the Announcement of New Methods by the Companies for the Status Epilepticus
An increase in the announcement of new methods by the companies for status epilepticus is expected to drive the market's growth.. For instance, on June 21, 2023, Marinus Pharmaceuticals announced a new method of use patent granted for IV Ganaxolone by the USPTO in status epilepticus.
Increase In FDA Clearance Of Companies' Software With The Inclusion Of Centers for Medicare and Medicaid Services (CMS) NTAP Coverage
An increase in FDA clearance of companies' software with the inclusion of CMS NTAP Coverage is expected to foster the growth of the global refractory status epileptics drugs market.
For instance, in August 2023, the FDA granted 510(k) clearance to Ceribell’s new software, named ClarityPro, for the diagnosis of electrographic status epilepticus (ESE) in adults above the age of 18, which became the first tool available in the market. Moreover, CMS gave new technology add-on payment (NTAP) for ClarityPro for up to $913.90 per eligible medicare patient case. Thus, owing to the above factors it is expected to drive the market's growth over the forecast period.
Stringent Regulatory Requirements
The pharmaceutical sector is governed by a number of laws and regulations, particularly when it comes to creating medications for severe illnesses such as refractory status epilepticus. It can be difficult and time-consuming to obtain regulatory approvals from organizations like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The availability of new RSE medications on the market may be delayed as a result of meeting these requirements, thus reducing treatment for patients options.
Segment Analysis
The global refractory status epileptics drugs market is segmented based on drug type, route of administration, distribution channel and region.
Benzodiazepines From The Drug Type to Hold a Dominant Position in the Market over the Forecast Period.
benzodiazepines from the drug type are expected to dominate the refractory status epileptics drugs market with a market share of 34.5%. For instance, In June 2022, anticonvulsant therapies in the benzodiazepine class successfully suppressed nearly 62% of all episodes of status epilepticus in children. First-line approaches usually include BZDs, which act to slow the excessive nerve cell activity that causes seizures.
Geographical Penetration
North America Holds The Largest Market Share In The Global Refractory Status Epileptics Drugs Market
North America dominates the global refractory status epileptics drugs market with a market share of around 41.3% in 2022. Furthermore, In March 2022, the FDA approved Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. CDD is a rare developmental epileptic encephalopathy (dysfunction of the brain) caused by CDKL5 gene mutations. Thus, owing to the above factors North America is expected to hold the largest share in the market over the forecast period.
Competitive Landscape
The major global players in the market include Pfizer, Almatica Pharma LLC., Teva Pharmaceuticals USA, Inc., Genentech, Inc., Viatris Inc., NAYZILAM, SiNi Pharma Pvt Ltd, H. Lundbeck A/S, Wellona Pharma and Bausch Health Companies Inc among others.
Market Segmentation
By Drug Type
• Benzodiazepines
o Lorazepam
o Diazepam
• Antiepileptic Drugs
o Phenytoin
o Fosphenytoin
o Valproic acid
o Others
• Anesthetic Agents
o Midazolam
o Propofol
• Barbiturates
o Pentobarbital
o Thiopental
o Others
By Route of Administration
• Oral
• Intravenous (IV)
• Intramuscular (IM)
• Sublingual or Buccal
• Others
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In February 2021, Marinus Pharmaceuticals stated that they have enrolled their first patient in the phase 3 RAISE clinical trial of intravenous (IV) ganaxolone.
Why Purchase the Report?
• To visualize the global refractory status epileptics drugs market segmentation based on drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cement market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global refractory status epileptics drugs market report would provide approximately 61 tables, 61 figures and 227 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in the Announcement of New Methods by the Companies for the Status Epilepticus
4.1.1.2. Increase In FDA Clearance Of Companies' Software with The Inclusion of CMS NTAP Coverage
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.3.1.1. Emerging Treatment Options
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Benzodiazepines *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Lorazepam
7.2.4. Diazepam
7.3. Antiepileptic Drugs
7.3.1. Phenytoin
7.3.2. Fosphenytoin
7.3.3. Valproic acid
7.3.4. Others
7.4. Anesthetic Agents
7.4.1. Midazolam
7.4.2. Propofol
7.5. Barbiturates
7.5.1. Pentobarbital
7.5.2. Thiopental
7.5.3. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Intravenous (IV)
8.4. Intramuscular (IM)
8.5. Sublingual or Buccal
8.6. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospitals
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacy
9.4. Online Pharmacy
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Treatment Type
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Pfizer *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Almatica Pharma LLC.
12.3. Teva Pharmaceuticals USA, Inc.
12.4. Genentech, Inc.
12.5. Viatris Inc.
12.6. NAYZILAM
12.7. SiNi Pharma Pvt Ltd
12.8. H. Lundbeck A/S
12.9. Wellona Pharma
12.10. Bausch Health Companies Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Pfizer, 4.	Key Developments, Almatica Pharma LLC., Teva Pharmaceuticals USA, Inc., Genentech, Inc., Viatris Inc., NAYZILAM, SiNi Pharma Pvt Ltd, H. Lundbeck A/S, Wellona Pharma, Bausch Health Companies Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Refractory Status Epileptics Drugs Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Refractory Status Epileptics Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Refractory Status Epileptics Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Refractory Status Epileptics Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Refractory Status Epileptics Drugs Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Refractory Status Epileptics Drugs Market Value, By Drug Type, 2022- 2031 (US$ Million)

Table 7 Global Refractory Status Epileptics Drugs Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Refractory Status Epileptics Drugs Market Value, By Route of Administration, 2022- 2031 (US$ Million)

Table 9 Global Refractory Status Epileptics Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Refractory Status Epileptics Drugs Market Value, By Distribution Channel, 2022- 2031 (US$ Million)

Table 11 Global Refractory Status Epileptics Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Refractory Status Epileptics Drugs Market Value, By Region, 2022- 2031 (US$ Million)

Table 13 North America Refractory Status Epileptics Drugs Market Value, By Drug Type, 2022- 2031 (US$ Million)

Table 14 North America Refractory Status Epileptics Drugs Market Value, By Route of Administration, 2022- 2031 (US$ Million)

Table 15 North America Refractory Status Epileptics Drugs Market Value, By Distribution Channel, 2022- 2031 (US$ Million)

Table 16 North America Refractory Status Epileptics Drugs Market Value, By Country, 2022- 2031 (US$ Million)

Table 17 South America Refractory Status Epileptics Drugs Market Value, By Drug Type, 2022- 2031 (US$ Million)

Table 18 South America Refractory Status Epileptics Drugs Market Value, By Route of Administration, 2022- 2031 (US$ Million)

Table 19 South America Refractory Status Epileptics Drugs Market Value, By Distribution Channel, 2022- 2031 (US$ Million)

Table 20 South America Refractory Status Epileptics Drugs Market Value, By Country, 2022- 2031 (US$ Million)

Table 21 Europe Refractory Status Epileptics Drugs Market Value, By Drug Type, 2022- 2031 (US$ Million)

Table 22 Europe Refractory Status Epileptics Drugs Market Value, By Route of Administration, 2022- 2031 (US$ Million)

Table 23 Europe Refractory Status Epileptics Drugs Market Value, By Distribution Channel, 2022- 2031 (US$ Million)

Table 24 Europe Refractory Status Epileptics Drugs Market Value, By Country, 2022- 2031 (US$ Million)

Table 25 Asia-Pacific Refractory Status Epileptics Drugs Market Value, By Drug Type, 2022- 2031 (US$ Million)

Table 26 Asia-Pacific Refractory Status Epileptics Drugs Market Value, By Route of Administration, 2022- 2031 (US$ Million)

Table 27 Asia-Pacific Refractory Status Epileptics Drugs Market Value, By Distribution Channel, 2022- 2031 (US$ Million)

Table 28 Asia-Pacific Refractory Status Epileptics Drugs Market Value, By Country, 2022- 2031 (US$ Million)

Table 29 Middle East & Africa Refractory Status Epileptics Drugs Market Value, By Drug Type, 2022- 2031 (US$ Million)

Table 30 Middle East & Africa Refractory Status Epileptics Drugs Market Value, By Route of Administration, 2022- 2031 (US$ Million)

Table 31 Middle East & Africa Refractory Status Epileptics Drugs Market Value, By Distribution Channel, 2022- 2031 (US$ Million)

Table 32 Pfizer: Overview

Table 33 Pfizer: Product Portfolio

Table 34 Pfizer: Key Developments

Table 35 Almatica Pharma LLC.: Overview

Table 36 Almatica Pharma LLC.: Product Portfolio

Table 37 Almatica Pharma LLC.: Key Developments

Table 38 Teva Pharmaceuticals USA, Inc.: Overview

Table 39 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 40 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 41 Genentech, Inc.: Overview

Table 42 Genentech, Inc.: Product Portfolio

Table 43 Genentech, Inc.: Key Developments

Table 44 Viatris Inc.: Overview

Table 45 Viatris Inc.: Product Portfolio

Table 46 Viatris Inc.: Key Developments

Table 47 NAYZILAM: Overview

Table 48 NAYZILAM: Product Portfolio

Table 49 NAYZILAM: Key Developments

Table 50 SiNi Pharma Pvt Ltd: Overview

Table 51 SiNi Pharma Pvt Ltd: Product Portfolio

Table 52 SiNi Pharma Pvt Ltd: Key Developments

Table 53 H. Lundbeck A/S: Overview

Table 54 H. Lundbeck A/S: Product Portfolio

Table 55 H. Lundbeck A/S: Key Developments

Table 56 Wellona Pharma: Overview

Table 57 Wellona Pharma: Product Portfolio

Table 58 Wellona Pharma: Key Developments

Table 59 Bausch Health Companies Inc.: Overview

Table 60 Bausch Health Companies Inc.: Product Portfolio

Table 61 Bausch Health Companies Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 2 Global Refractory Status Epileptics Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 3 Global Refractory Status Epileptics Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 4 Global Refractory Status Epileptics Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Refractory Status Epileptics Drugs Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Refractory Status Epileptics Drugs Market Y-o-Y Growth, By Drug Type, 2022- 2031 (%)

Figure 7 Benzodiazepines Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 8 Antiepileptic Drugs Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 9 Anesthetic Agents Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 10 Barbiturates Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 11 Global Refractory Status Epileptics Drugs Market Y-o-Y Growth, By Route of Administration, 2022- 2031 (%)

Figure 12 Oral Route of Administration in Global Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 13 Intravenous (IV) Route of Administration in Global Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 14 Intramuscular (IM) Route of Administration in Global Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 15 Sublingual or Buccal Route of Administration in Global Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 16 Rectal (PR) Route of Administration in Global Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 17 Others Route of Administration in Global Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 18 Global Refractory Status Epileptics Drugs Market Y-o-Y Growth, By Distribution Channel, 2022- 2031 (%)

Figure 19 Hospital Pharmacy Distribution Channel in Global Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 20 Retail Pharmacy Distribution Channel in Global Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 21 Online Pharmacy Distribution Channel in Global Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 22 Global Refractory Status Epileptics Drugs Market Y-o-Y Growth, By Region, 2022- 2031 (%)

Figure 23 North America Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 24 Asia-Pacific Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 25 Europe Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 26 South America Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 27 Middle East and Africa Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 28 North America Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 29 North America Refractory Status Epileptics Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 30 North America Refractory Status Epileptics Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 31 North America Refractory Status Epileptics Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 32 North America Refractory Status Epileptics Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 33 South America Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 34 South America Refractory Status Epileptics Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 35 South America Refractory Status Epileptics Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 36 South America Refractory Status Epileptics Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 37 South America Refractory Status Epileptics Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 38 Europe Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 39 Europe Refractory Status Epileptics Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 40 Europe Refractory Status Epileptics Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 41 Europe Refractory Status Epileptics Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 42 Europe Refractory Status Epileptics Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 43 Asia-Pacific Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 44 Asia-Pacific Refractory Status Epileptics Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 45 Asia-Pacific Refractory Status Epileptics Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 46 Asia-Pacific Refractory Status Epileptics Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 47 Asia-Pacific Refractory Status Epileptics Drugs Market Share, By Country, 2022 & 2031 (%)

Figure 48 Middle East & Africa Refractory Status Epileptics Drugs Market Value, 2022- 2031 (US$ Million)

Figure 49 Middle East & Africa Refractory Status Epileptics Drugs Market Share, By Drug Type, 2022 & 2031 (%)

Figure 50 Middle East & Africa Refractory Status Epileptics Drugs Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 51 Middle East & Africa Refractory Status Epileptics Drugs Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 52 Pfizer: Financials

Figure 53 Almatica Pharma LLC.: Financials

Figure 54 Teva Pharmaceuticals USA, Inc.: Financials

Figure 55 Genentech, Inc.: Financials

Figure 56 Viatris Inc.: Financials

Figure 57 NAYZILAM: Financials

Figure 58 SiNi Pharma Pvt Ltd: Financials

Figure 59 H. Lundbeck A/S: Financials

Figure 60 Wellona Pharma: Financials

Figure 61 Bausch Health Companies Inc.: Financials

세계 난치성 간질 치료제 시장 – 2023-2030

Global Refractory Status Drugs Epileptics Market - 2023-2030